GlobeNewswire

Open Society Foundations Announce Inaugural Soros Arts Fellows

Dela

New fellowship honors eight artists engaging creatively with public space

New York, May 04, 2018 (GLOBE NEWSWIRE) -- The Open Society Foundations are pleased to announce the first recipients of the Soros Arts Fellowship, a new initiative to support innovative mid-career artists using art and public space to advance pluralistic, democratic, and just societies. The eight fellows selected will each receive an $80,000 stipend to realize an ambitious socially engaged art project over the next 18 months.

With a long history of supporting arts and culture to advance social change, the Open Society Foundations today recognizes the importance of artists' contributions and the necessity of using creativity as a response to increased repression across the globe. As spaces for public engagement are shrinking, the arts are often the last refuge of collective imagination.

"Whether in democracies with longstanding traditions of supporting freedom of expression or in countries undergoing political transition, artists working in public spaces can contest oppression, make hope tangible, and create momentum for change," said Rashida Bumbray, senior program manager of the Open Society Foundations' Arts Exchange. "This fellowship acknowledges the critical role that the arts can play in confronting obstacles to open society, and we are delighted to name these eight remarkable artists as our first cohort of fellows."

The 2018 Soros Arts Fellows originate from the Democratic Republic of Congo, Ghana, Haiti, Morocco, Romania, Sudan, and the United States. Each is pursuing projects of their own design-including an arts-based organizing campaign against public conviction registries in the United States; a citizen perspective film on life in the historically overlooked municipality of Lubunga, in the Democratic Republic of Congo; and a cultural resistance movement against the privatization of natural resources in the Moroccan Benslimane forest.

The Soros Arts Fellowship was designed with a clear awareness of the challenges faced by artists and cultural producers doing social engaged work that is largely disconnected from the art market. The fellowship provides artists with the resources to develop a large-scale project on their own terms in their own local contexts. Over time, the Soros Arts Fellowship aims to build and strengthen a community of global allies.

The selection committee included Omar Berrada, curator and director of Dar al-Ma'mûn; Leslie Hewitt, artist and assistant professor at The Cooper Union; Sandra Jackson-Dumont, Frederick P. and Sandra P. Rose Chairman of Education at the Metropolitan Museum of Art; Nato Thompson, artistic director of Philadelphia Contemporary; Arts Exchange staff Rashida Bumbray, Tatiana Mouarbes, and Lauren Agosta; and colleagues from the Open Society Foundations. As part of the fellowship, recipients have the opportunity for personalized professional development through mentorship by Ruby Lerner, founder of Creative Capital.

2018 Soros Arts FellowsKHALID ALBAIH (Copenhagen, Denmark) will create a platform to connect artists and arts patrons around the world, forging an online community and helping to democratize public space and provide artists with access to spaces for their work.

NANA OFORIATTA-AYIM (Accra, Ghana) will create a series of films exploring the cultural and historical kaleidoscope of each region in Ghana, as well as their most glaring-and often unspoken-ills, building sustainable interventions through partnership with local communities and foundations.

HASSAN DARSI (Casablanca, Morocco) will work with residents of Beni Aïssi village in the Benslimane forest to create a cultural resistance movement against privatization of natural resources, which will include a citizen's cultural walk to build solidarity and new artistic paths for interaction.

LAILA HIDA (Marrakech, Morocco) will collaborate with artists and activists to engage local communities to create new spaces for collective social interaction, community empowerment, and the reactivation of public spaces around Marrakech.

FAUSTIN LINYEKULA (Kisangani, Democratic Republic of Congo) will collaborate with 30 artists in Kisangani on Lubunga Files, a four-part film portraying citizen perspectives on life in Lubunga, emphasizing the importance of locally produced narratives, images, and reflections.

GUY REGIS, JR. (Port-au-Prince, Haiti) will infuse the streets of Port-au-Prince with poetic forms to shift public opinion around the symbolic and literal forms of violence against youth in these spaces.

LAURIE JO REYNOLDS (Chicago, Illinois, United States) will organize a multidisciplinary campaign with diverse community partners to oppose conviction-based registries, housing restrictions, and exclusion zones, and instead advocate for policies that prevent victimization, support survivors, and assist people in leading positive and productive lives after a criminal conviction.

ALINA SERBAN (Bucharest, Romania) is producing a revised version of her work The Great Shame, the first play solely focused on the history of Roma slavery, to shift discriminatory narratives and advocate for the equal rights and treatment of the Roma people.

Attachment

Mai Lynn Miller Nguyen
Open Society Foundations
(212) 548-0386
mailynn.miller@opensocietyfoundations.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Open Society Foundations via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum